{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T20:58:51Z","timestamp":1790283531943,"version":"4.1.0"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales de Pathologie"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.annpat.2026.09.001","type":"journal-article","created":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T19:59:51Z","timestamp":1790279991000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Actualit\u00e9s dans le grading des astrocytomes, IDH-mut\u00e9s\u00a0: \u00e9tude de l\u2019impact de l\u2019update 12\u00a0du cIMPACT-NOW"],"prefix":"10.1016","author":[{"given":"Arnault","family":"Tauzi\u00e8de-Espariat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"M\u00e9tais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farah","family":"Sassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rapha\u00ebl","family":"Saffroy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascale","family":"Varlet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.annpat.2026.09.001_bib0185","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021\u00a0WHO Classification of tumors of the central nervous system: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.annpat.2026.09.001_bib0190","series-title":"WHO classification of tumours of the central nervous system","author":"Louis","year":"2016"},{"key":"10.1016\/j.annpat.2026.09.001_bib0195","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s00401-007-0243-4","article-title":"The 2007\u00a0WHO classification of tumours of the central nervous system","volume":"114","author":"Louis","year":"2007","journal-title":"Acta Neuropathol (Berl)"},{"key":"10.1016\/j.annpat.2026.09.001_bib0200","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1054\/jocn.2000.0829","article-title":"The 2000\u00a0World Health Organization classification of tumours of the nervous system","volume":"8","author":"Gonzales","year":"2001","journal-title":"J Clin Neurosci"},{"key":"10.1016\/j.annpat.2026.09.001_bib0205","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/j.1750-3639.1993.tb00752.x","article-title":"The new WHO classification of brain tumours","volume":"3","author":"Kleihues","year":"1993","journal-title":"Brain Pathol"},{"key":"10.1016\/j.annpat.2026.09.001_bib0210","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1093\/neuonc\/noab227","article-title":"Impact of the methylation classifier and ancillary methods on CNS tumor diagnostics","volume":"24","author":"Wu","year":"2022","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.annpat.2026.09.001_bib0215","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.ccell.2025.11.002","article-title":"Advancing CNS tumor diagnostics with expanded DNA methylation-based classification","volume":"44","author":"Sill","year":"2026","journal-title":"Cancer Cell"},{"key":"10.1016\/j.annpat.2026.09.001_bib0220","doi-asserted-by":"crossref","first-page":"vdae228","DOI":"10.1093\/noajnl\/vdae228","article-title":"cIMPACT-NOW update 9: Recommendations on utilization of genome-wide DNA methylation profiling for central nervous system tumor diagnostics","volume":"7","author":"Aldape","year":"2025","journal-title":"Neuro Oncol Adv"},{"key":"10.1016\/j.annpat.2026.09.001_bib0225","first-page":"noae170","article-title":"cIMPACT-NOW Update 8: clarifications on molecular risk parameters and recommendations for WHO grading of meningiomas","author":"Sahm","year":"2024","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.annpat.2026.09.001_bib0230","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s00401-018-1913-0","article-title":"cIMPACT-NOW update 3: recommended diagnostic criteria for \u201cDiffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV\u201d","volume":"136","author":"Brat","year":"2018","journal-title":"Acta Neuropathol (Berl)"},{"key":"10.1016\/j.annpat.2026.09.001_bib0235","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s00401-020-02127-9","article-title":"cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas","volume":"139","author":"Brat","year":"2020","journal-title":"Acta Neuropathol (Berl)"},{"key":"10.1016\/j.annpat.2026.09.001_bib0240","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/bpa.12866","article-title":"cIMPACT-NOW update 7: advancing the molecular classification of ependymal tumors","volume":"30","author":"Ellison","year":"2020","journal-title":"Brain Pathol"},{"key":"10.1016\/j.annpat.2026.09.001_bib0245","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1007\/s00401-019-01987-0","article-title":"cIMPACT-NOW update 4: diffuse gliomas characterized by MYB, MYBL1, or FGFR1\u00a0alterations or BRAFV600E mutation","volume":"137","author":"Ellison","year":"2019","journal-title":"Acta Neuropathol (Berl)"},{"key":"10.1016\/j.annpat.2026.09.001_bib0250","first-page":"4","article-title":"cIMPACT-NOW update 6: new entity and diagnostic principle recommendations of the cIMPACT-Utrecht meeting on future CNS tumor classification and grading","volume":"30","author":"Louis","year":"2020","journal-title":"Brain Pathol Zurich Switz"},{"key":"10.1016\/j.annpat.2026.09.001_bib0255","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s00401-018-1826-y","article-title":"cIMPACT-NOW update 2: diagnostic clarifications for diffuse midline glioma, H3\u00a0K27M-mutant and diffuse astrocytoma\/anaplastic astrocytoma, IDH-mutant","volume":"135","author":"Louis","year":"2018","journal-title":"Acta Neuropathol (Berl)"},{"key":"10.1016\/j.annpat.2026.09.001_bib0260","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s00401-018-1808-0","article-title":"cIMPACT-NOW update 1: not otherwise specified (NOS) and not elsewhere classified (NEC)","volume":"135","author":"Louis","year":"2018","journal-title":"Acta Neuropathol (Berl)"},{"key":"10.1016\/j.annpat.2026.09.001_bib0265","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1093\/neuonc\/noag108","article-title":"cIMPACT-NOW update 12: refining pathology-based risk stratification and grading for IDH-mutant gliomas","volume":"28","author":"Brat","year":"2026","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.annpat.2026.09.001_bib0270","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1055\/s-0038-1636430","article-title":"Grading of diffuse astrocytic gliomas: a review of studies before and after the advent of IDH testing","volume":"38","author":"von Deimling","year":"2018","journal-title":"Semin Neurol"},{"key":"10.1016\/j.annpat.2026.09.001_bib0275","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00401-023-02662-1","article-title":"Improved prognostic stratification of patients with isocitrate dehydrogenase-mutant astrocytoma","volume":"147","author":"Weller","year":"2024","journal-title":"Acta Neuropathol (Berl)"},{"key":"10.1016\/j.annpat.2026.09.001_bib0280","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1093\/neuonc\/noac282","article-title":"Mitotic count is prognostic in IDH mutant astrocytoma without homozygous deletion of CDKN2A\/B. Results of consensus panel review of EORTC trial 26053 (CATNON) and EORTC trial 22033-26033","volume":"25","author":"Kros","year":"2023","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.annpat.2026.09.001_bib0285","doi-asserted-by":"crossref","first-page":"21190","DOI":"10.18632\/oncotarget.8498","article-title":"Ki-67\u00a0proliferation index but not mitotic thresholds integrates the molecular prognostic stratification of lower grade gliomas","volume":"7","author":"Duregon","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.annpat.2026.09.001_bib0290","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1007\/s00401-021-02291-6","article-title":"Non-IDH1-R132H IDH1\/2\u00a0mutations are associated with increased DNA methylation and improved survival in astrocytomas, compared to IDH1-R132H mutations","volume":"141","author":"Tesileanu","year":"2021","journal-title":"Acta Neuropathol (Berl)"},{"key":"10.1016\/j.annpat.2026.09.001_bib0295","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/bpa.12801","article-title":"IDH mutant lower grade (WHO Grades II\/III) astrocytomas can be stratified for risk by CDKN2A, CDK4\u00a0and PDGFRA copy number alterations","volume":"30","author":"Yang","year":"2020","journal-title":"Brain Pathol"},{"key":"10.1016\/j.annpat.2026.09.001_bib0300","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1093\/jnen\/nlaa083","article-title":"The prognostic significance of\u00a0RB and PI3K pathway alterations in IDH-mutant grade II\/III astrocytomas","volume":"79","author":"Richardson","year":"2020","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1016\/j.annpat.2026.09.001_bib0305","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1093\/neuonc\/noae258","article-title":"Canonical amplifications and CDKN2A\/B loss refine IDH1\/2-mutant astrocytoma prognosis","volume":"27","author":"Ghosh","year":"2025","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.annpat.2026.09.001_bib0310","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1093\/neuonc\/noaf133","article-title":"Clinical, molecular, and radiological predictors of prognosis in newly diagnosed astrocytoma, IDH-mutant, WHO grade 4","volume":"27","author":"Lasica","year":"2025","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.annpat.2026.09.001_bib0315","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1007\/s00401-023-02639-0","article-title":"CDKN2A\/B mutations and allele-specific alterations stratify survival outcomes in IDH-mutant astrocytomas","volume":"146","author":"Hickman","year":"2023","journal-title":"Acta Neuropathol (Berl)"},{"key":"10.1016\/j.annpat.2026.09.001_bib0320","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1093\/neuonc\/nox132","article-title":"Prognostic relevance of genetic alterations in diffuse lower-grade gliomas","volume":"20","author":"Aoki","year":"2018","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.annpat.2026.09.001_bib0325","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1093\/neuonc\/noag069","article-title":"Expanding the molecular grading criteria in IDH-mutant astrocytoma","volume":"28","author":"Virata","year":"2026","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.annpat.2026.09.001_bib0330","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s40478-017-0443-7","article-title":"Multidimensional scaling of diffuse gliomas: application to the 2016\u00a0World Health Organization classification system with prognostically relevant molecular subtype discovery","volume":"5","author":"Cimino","year":"2017","journal-title":"Acta Neuropathol Commun"},{"key":"10.1016\/j.annpat.2026.09.001_bib0335","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1093\/neuonc\/noz052","article-title":"Targeted copy number analysis outperforms histologic grading in predicting patient survival for WHO grades II\/III IDH-mutant astrocytomas","volume":"21","author":"Cimino","year":"2019","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.annpat.2026.09.001_bib0340","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s40478-015-0265-4","article-title":"PI3\u00a0kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients","volume":"3","author":"Draaisma","year":"2015","journal-title":"Acta Neuropathol Commun"},{"key":"10.1016\/j.annpat.2026.09.001_bib0345","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s00401-025-02928-w","article-title":"EGFR alteration is an adverse prognostic factor in IDH-mutant astrocytoma","volume":"150","author":"Slocum","year":"2025","journal-title":"Acta Neuropathol (Berl)"},{"key":"10.1016\/j.annpat.2026.09.001_bib0350","doi-asserted-by":"crossref","first-page":"6761","DOI":"10.1038\/s41598-023-32153-y","article-title":"Genomic profiles of IDH-mutant gliomas: MYCN-amplified IDH-mutant astrocytoma had the worst prognosis","volume":"13","author":"Lee","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.annpat.2026.09.001_bib0355","doi-asserted-by":"crossref","first-page":"e70045","DOI":"10.1002\/2056-4538.70045","article-title":"MYCN amplification defines an aggressive phenotype in IDH-mutant gliomas","volume":"11","author":"Xie","year":"2025","journal-title":"J Pathol Clin Res"},{"key":"10.1016\/j.annpat.2026.09.001_bib0180","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1093\/neuonc\/noae009","article-title":"Prognostic value of DNA methylation subclassification, aneuploidy, and CDKN2A\/B homozygous deletion in predicting clinical outcome of IDH mutant astrocytomas","volume":"26","author":"Galbraith","year":"2024","journal-title":"Neuro Oncol"}],"container-title":["Annales de Pathologie"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0242649826001604?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0242649826001604?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T19:59:55Z","timestamp":1790279995000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0242649826001604"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":36,"alternative-id":["S0242649826001604"],"URL":"https:\/\/doi.org\/10.1016\/j.annpat.2026.09.001","relation":{},"ISSN":["0242-6498"],"issn-type":[{"value":"0242-6498","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Actualit\u00e9s dans le grading des astrocytomes, IDH-mut\u00e9s\u00a0: \u00e9tude de l\u2019impact de l\u2019update 12\u00a0du cIMPACT-NOW","name":"articletitle","label":"Article Title"},{"value":"Annales de Pathologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annpat.2026.09.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}